Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$0.16 - $1.64 $7,171 - $73,506
44,821 Added 3.84%
1,211,726 $218,000
Q2 2023

Aug 11, 2023

BUY
$0.66 - $1.22 $19,076 - $35,262
28,904 Added 2.54%
1,166,905 $1.4 Million
Q1 2023

May 15, 2023

BUY
$0.59 - $1.04 $13,049 - $23,002
22,118 Added 1.98%
1,138,001 $785,000
Q4 2022

Feb 13, 2023

BUY
$0.66 - $259.46 $5,315 - $2.09 Million
8,054 Added 0.73%
1,115,883 $757,000
Q3 2022

Nov 14, 2022

BUY
$0.65 - $278.68 $69,050 - $29.6 Million
106,232 Added 10.61%
1,107,829 $1.14 Million
Q2 2022

Aug 12, 2022

SELL
$0.51 - $0.93 $314,216 - $572,982
-616,110 Reduced 38.09%
1,001,597 $681,000
Q1 2022

May 13, 2022

BUY
$0.84 - $1.71 $27,483 - $55,949
32,719 Added 2.06%
1,617,707 $1.36 Million
Q4 2021

Feb 11, 2022

SELL
$1.59 - $2.38 $217,335 - $325,319
-136,689 Reduced 7.94%
1,584,988 $2.58 Million
Q3 2021

Nov 12, 2021

BUY
$1.69 - $2.89 $610,137 - $1.04 Million
361,028 Added 26.53%
1,721,677 $4.15 Million
Q2 2021

Aug 13, 2021

BUY
$2.64 - $6.32 $2.16 Million - $5.17 Million
817,695 Added 150.6%
1,360,649 $3.59 Million
Q1 2021

May 12, 2021

BUY
$1.35 - $4.99 $312,303 - $1.15 Million
231,336 Added 74.24%
542,954 $2.71 Million
Q4 2020

Feb 12, 2021

BUY
$0.74 - $2.01 $116,343 - $316,014
157,221 Added 101.83%
311,618 $492,000
Q4 2019

Feb 13, 2020

BUY
$0.72 - $1.52 $496 - $1,048
690 Added 0.45%
154,397 $206,000
Q2 2019

Aug 14, 2019

BUY
$2.11 - $3.3 $242,922 - $379,925
115,129 Added 298.43%
153,707 $336,000
Q1 2019

May 14, 2019

SELL
$1.45 - $8.1 $275,265 - $1.54 Million
-189,838 Reduced 83.11%
38,578 $129,000
Q4 2018

Feb 13, 2019

BUY
$5.7 - $11.7 $1.3 Million - $2.67 Million
228,416 New
228,416 $43,000

Others Institutions Holding SEEL

# of Institutions
1
Shares Held
40.5K
Call Options Held
0
Put Options Held
0

About SEELOS THERAPEUTICS, INC.


  • Ticker SEEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 106,691,000
  • Market Cap $40.5M
  • Description
  • Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...
More about SEEL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.